HOME>News & Media
Healthy bodies, healthy lives

 

Sunovion Pharmaceuticals Inc. is a fully integrated, research-based specialty pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs.
More >>

2012 | 2011 | 2010 | 2009 | 2008 DSPA 2009 Press Releases

 Date  Title
12/08/10 Latuda® (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
12/04/10 New STEDESA™ Clinical Data Presented at American Epilepsy Society Annual Meeting
10/28/10 FDA approves once-daily LATUDA® (lurasidone HCl) for the treatment of patients with schizophrenia
10/12/10 Sunovion Pharmaceuticals Inc. Announces Company Name Change
07/15/10 Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.
06/30/10 Sepracor Reports Preliminary Results from a Second Phase III Study for OMNARIS® HFA Nasal Aerosol in Seasonal Allergic Rhinitis
05/03/10 FDA Provides Complete Response to Sepracor's New Drug Application For STEDESA™
03/10/10 Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
02/19/10 Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
01/27/10 FDA Extends PDUFA Action Date for STEDESA™ New Drug Application
01/04/10 Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia
Home | Who We Are | Our Products | For Our Patients | Working at Sunovion | For Healthcare Professionals | Site Map | Terms of Use | Privacy Policy | About DSP
Sunovion is a trademark of Dainippon Sumitomo Pharma Co., Ltd., Osaka, Japan. © 2012 Sunovion Pharmaceuticals Inc., Marlborough, MA 01752. All rights reserved.